AVCNF - Avicanna Hosts Symposium on Cannabinoid-based Medicine | Benzinga
TORONTO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that the Company will host a medical symposium entitled "Cannabinoid-based Medicine in the Canadian Healthcare System – From Emerging Evidence to Clinical Practice" at the MaRS Discovery District, Toronto, Monday, May 13, 2024.
The symposium, with registration limited to health care practitioners and researchers, will cover a range of topics including emerging evidence and practical clinical applications of cannabinoid-based medicine. The event will feature key opinion leaders, clinicians, researchers, and scientists from various academic, research and clinical organizations and hospitals and industry. Speakers include:
| Dr. Camila Sofia Arriagada Egnen SickKids, The Hospital for Sick Children |
| Dr. Karolina Urban Avicanna Inc. |
| Dr. Alan Bell University of Toronto |
| Samantha Aitken, RPh MyMedi.ca |
| Dr. Hance Clarke Toronto General Hospital University Health Network |
| Aras Azadian Avicanna Inc. |
| Dr. Carlo DeAngelis Sunnybrook Health Sciences Centre |
| Andrew Bevan Spectrum Therapeutics |